NCT01349712

Brief Summary

The purpose of this study is to measure prothrombin time (PT) on an experimental device and a commercially available device on persons receiving coumadin (warfarin)treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2011

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 29, 2011

Completed
2 days until next milestone

Study Start

First participant enrolled

May 1, 2011

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 9, 2011

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

May 9, 2011

Status Verified

May 1, 2011

Enrollment Period

6 months

First QC Date

April 29, 2011

Last Update Submit

May 5, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • PT/INR values from the experimental device will be statistically correlated to results obtained from a commercially available device

    To determine the correlation of PT/INR values between an experimental and commercial device.

    Fives days to collect data and up to two weeks to generate correlation graph

Study Arms (1)

Coumadin (warfarin)

Subjects are required to be currently receiving coumadin (warfarin) treatment.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects currently receving coumadin(warfarin) treatment

You may qualify if:

  • Currently taking coumadin (warfarin)
  • Aged 18 years or older
  • Able and willing to provide informed consent
  • Can understand (read and write) English

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

White River Diagnostic Clinic

Batesville, Arkansas, 72501, United States

Location

MeSH Terms

Conditions

Blood Coagulation Disorders

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Richard Ward, Pharm D

    Harding University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 29, 2011

First Posted

May 9, 2011

Study Start

May 1, 2011

Primary Completion

November 1, 2011

Study Completion

November 1, 2011

Last Updated

May 9, 2011

Record last verified: 2011-05

Locations